Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder

Journal of Psychiatric Research

Volumn 44, Issue 2, 2010, Pages 90-98

  Hunter, Aimee M ^a   Muthén, Bengt O ^b   Cook, Ian A ^a   Leuchter, Andrew F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressants; Cordance; Depression; EEG; Growth mixture modeling; Statistical models

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; SYMPTOM;

EID: 73749084835     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.06.006     Document Type: Article

References (43)

1. Akiskal H.S. Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity?. Journal of Affective Disorders 73 (1993) 1-5
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159 Suppl. (2002) 1-50
3. Bares M., Brunovsky M., Kopecek M., Stopkova P., Novak T., Kozeny J., et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. Journal of Psychiatric Research 41 (2007) 319-325
4. Bares M., Brunovsky M., Kopecek M., Novak T., Stopkova P., Kozeny J., et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. European Psychiatry 23 (2008) 350-355
5. Beasley Jr. C.M., Koke S.C., Nilsson M.E., and Gonzales J.S. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clinical Therapeutics 22 (2000) 1319-1330
6. Chelben J., Strous R.D., Lustig M., and Baruch Y. Remission of SSRI-induced akathisia after switch to nefazodone. Journal of Clinical Psychiatry 62 (2001) 570-571
7. Cook I.A., O'Hara R., Uijtdehaage S.H., Mandelkern M., and Leuchter A.F. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalography and Clinical Neurophysiology 107 (1998) 408-414
8. Cook I.A., Leuchter A.F., Morgan M., Witte E., Stubbeman W.F., Abrams M., et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27 (2002) 120-131
9. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF. Midline and right front brain function as a biomarker of remission in major depression. Psychiatic Research Neuroimaging, in press.
10. Cuijpers P., van Lier P.A., van Straten A., and Donker M. Examining differential effects of psychological treatment of depressive disorder: an application of trajectory analyses. Journal of Affective Disorders 89 (2005) 137-146
11. Cusin C., Fava M., Amsterdam J.D., Quitkin F.M., Reimherr F.W., Beasley Jr. C.M., et al. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. Journal of Clinical Psychiatry 68 (2007) 52-57
12. Donovan S.J., Quitkin F.M., Stewart J.W., Ocepek-Welikson K., Harrison W., McGrath P.J., et al. Duration of antidepressant trials: clinical and research implications. Journal of Clinical Psychopharmacology 14 (1994) 64-66
13. Fava M., Rush A.J., Alpert J.E., Balasubramani G.K., Wisniewski S.R., Carmin C.N., et al. Trivedi MH: difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. American Journal of Psychiatry 165 (2008) 342-351
14. First MB, Spitzer RL, Gibbon M, Williams J. Structured clinical interview for DSM-IV axis I disorders, patient edition (SCID-I/P, version 2.0). New York; 1995.
15. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23 (1960) 56-62
16. Hunter A.M., Cook I.A., and Leuchter A.F. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. Psychiatric Clinics of North America 30 (2007) 105-124
17. Kaplan E.M. Antidepressant noncompliance as a factor in the discontinuation syndrome. Journal of Clinical Psychiatry 58 Suppl. 7 (1997) 31-35
18. Leuchter A.F., Uijtdehaage S.H., Cook I.A., O'Hara R., and Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Research 90 (1999) 125-140
19. Leuchter AF, Cook IA, Hunter AM, Morgan ML, McGrouther CC, Abrams M. Functional brain changes associated with remission of major depressive disorder. Poster presented at the Society of Biological Psychiatry Meeting, Atlanta, GA., 2005.
20. Leuchter A.F., Cook I.A., DeBrota D.J., Hunter A.M., Potter W.Z., McGrouther C.C., et al. Changes in brain function during administration of venlafaxine or placebo to normal subjects. Clinical EEG and Neuroscience 39 (2008) 175-181
21. Muthén B., and Muthén L.K. Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcoholism: Clinical and Experimental Research 24 (2000) 882-891
22. Muthén B., and Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55 (1999) 463-469
23. Muthén B, Muthén L. Mplus version 5 software users guide;1998-2008.
24. Muthén B., Brown C.H., Masyn K., Jo B., Khoo S.T., Yang C.C., et al. General growth mixture modeling for randomized preventive interventions. Biostatistics 3 (2002) 459-475
25. Muthén B. Latent variable analysis: growth mixture modeling and related techniques for longitudinal data. In: Kaplan D. (Ed). Handbook of quantitative methodology for the social sciences (2004), Sage Publications, Newbury Park, CA 345-368
26. Muthén B., and Asparouhov T. Growth mixture modeling: analysis with non-Gaussian random effects. In: Fitzmaurice G., Davidian M., Verbeke G., and Molenberghs G. (Eds). Advances in longitudinal data analysis (2008), Advance, Boca Raton 143-165
27. Muthén B, Brown H. Estimating drug effects in the presence of placebo response: Causal inference using growth mixture modeling. Statistics in Medicine, in press
28. Muthén B, Brown H, Leuchter AF, Hunter AM. Applying growth mixture modeling to randomized trials of depression medication. In: Strout PE, editor. Causality and psychopathology: finding the determinants of disorders and their cures. Unpublished technical report 2008. Available from: http://www.statmodel.com/download/APPA2008March27.pdf.
29. Nierenberg A.A., Farabaugh A.H., Alpert J.E., Gordon J., Worthington J.J., Rosenbaum J.F., et al. Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 157 (2000) 1423-1428
30. Nylund K.L., Asparouhov T., and Muthén B.O. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Structural Equation Modeling: A Multidisciplinary Journal 14 (2007) 535-569
31. Papakostas G.I., Petersen T., Sklarsky K.G., Nierenberg A.A., Alpert J.E., and Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Research 149 (2007) 195-200
32. Perahia D.G., Pritchett Y.L., Kajdasz D.K., Bauer M., Jain R., Russell J.M., et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Journal of Psychiatric Research 42 (2008) 22-34
33. Posternak M.A., and Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry 66 (2005) 148-158
34. Quitkin F.M., Rabkin J.G., Ross D., and Stewart J.W. Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 41 (1984) 782-786
35. Quitkin F.M., Rabkin J.D., Markowitz J.M., Stewart J.W., McGrath P.J., and Harrison W. Use of pattern analysis to identify true drug response. A replication. Archives of General Psychiatry 44 (1987) 259-264
36. Quitkin F.M., McGrath P.J., Rabkin J.G., Stewart J.W., Harrison W., Ross D.C., et al. Different types of placebo response in patients receiving antidepressants. American Journal of Psychiatry 148 (1991) 197-203
37. Quitkin F.M., McGrath P.J., Stewart J.W., Taylor B.P., and Klein D.F. Can the effects of antidepressants be observed in the first two weeks of treatment?. Neuropsychopharmacology 15 (1996) 390-394
38. Ramaswamy V., DeSarbo W., Reibstein D., and Robinson W. An empirical pooling approach for estimating marketing mix elasticities with PIMS data. Marketing Science 12 (1993) 103-124
39. Sachs G.S., Koslow C.L., and Ghaemi S.N. The treatment of bipolar depression. Bipolar Disorders 2 (2000) 256-260
40. Stassen H.H., Angst J., Hell D., Scharfetter C., and Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. Journal of Clinical Psychiatry 68 (2007) 1195-1205
41. Stulz N., and Lutz W. Multidimensional patterns of change in outpatient psychotherapy: the phase model revisited. Journal of Clinical Psychology 63 (2007) 817-833
42. Stulz N., Lutz W., Leach C., Lucock M., and Barkham M. Shapes of early change in psychotherapy under routine outpatient conditions. Journal of Consulting and Clinical Psychology 75 (2007) 864-874
43. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. STAR*D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163 (2006) 28-40